Screen Shot 2019-01-31 at 9.20.10 PM.png


Screen Shot 2019-01-31 at 9.24.17 PM.png

PATRICK JAMES LYNCH, Director/Producer

Laurie High-Res.jpeg


  • Founder and president of Save One Life, Inc.

  • President of LA Kelley Communications, Inc.

  • Author of eleven books on hemophilia, including Raising a Child with Hemophilia.

  • Founder of Project SHARE, which donates life-saving medicine to people with hemophilia worldwide.

  • Global coach for leaders in developing countries, to start and develop hemophilia nonprofits.

  • Has visited 29 developing countries to work with hemophilia patients and nonprofits.


Bombardier Blood made possible by

Octa Logo for Filmmakers Page.png
  • For more than 30 years, Octapharma has been focused exclusively on the development and manu- facture of high-quality human proteins for use as medical treatments.

  • Patients in more than 100 countries are treated with Octapharma therapies for serious chronic and genetic disorders in hematology, immunotherapy and critical care.

  • Headquartered in Lachen, Switzerland, Octapharma continuously develops sophisticated technolo- gies to help improve the safety of human protein products for patients.

  • The company’s American subsidiary, Octapharma USA, located in Hoboken, New Jersey, last year introduced NUWIQ®, Antihemophilic Factor (Recombinant) to the U.S. bleeding disorders community.

  • Octapharma’s commitment to patients also is evident in its product for von Willebrand Disease (VWD) patients – WILATE®, von Willebrand Factor/Coagulation Factor VIII Complex (Human).

  • Octapharma was the first company to apply the solvent/detergent virus inactivation process to the routine production of Factor VIII concentrates vital to the bleeding disorders community.

  • Octapharma operates 80 plasma collection centers in the U.S. and Germany, as well as a new state-of-the-art testing laboratory in Charlotte, North Carolina.

  • The company’s global presence includes more than 6,200 employees, 32 international locations, six production facilities, and five research and development centers.

Additional support provided by


The Coalition for Hemophilia B was founded in 1990 by Joyce and John Taylor when their son was diagnosed with moderate/severe Hemophilia B. Formed as a way of providing information about treatment options to patients and their families, as well as instigating and funding research and product development, the Coalition provides information about treatment that will improve quality of life, works to define new treatment modalities, and support efforts to eliminate the disease.